Renato Dulbecco died on February 19, 2012, three days shy of his 98 th birthday. He had a remarkable career in science that spanned over 60 years. In 1948 he published, with Salvador Luria, his first real scientific paper in Genetics on bacteriophage genetics and in 2008 published his last paper in PNAS on breast cancer tumor-initiating cells. In the intervening years, Dulbecco helped to decipher how tumor viruses integrate into genomes and transform normal cells into cancer cells and propelled biology into the genomic era with his broad thinking and prescient foresight.
Dulbecco was born in Cantanzaro in Southern Italy in 1914. He trained as a medical doctor, specializing in pathology, and received his degree from the University of Torino in 1936. After graduating, he served 2 years in the military, before returning to train in pathology. He then decided that he was more interested in basic research than medicine and began working on cell culture techniques with Giuseppe Levi in his institute in Torino.
At the start of World War II, Dulbecco was called up again. He fought on the Russian front and was seriously wounded, leading to his discharge. After the German occupation of Italy, he joined the resistance, acting as physician for local partisan units in the Piemonte region.
Following the war Dulbecco enrolled again at the university to take physics courses and then returned to the Levi Institute, where he had already met Rita Levi-Montalcini and Salvador Luria, who were fellow students. Luria had been in the USA since the beginning of the war, and he and Levi-Montalcini urged Dulbecco to move to the US to pursue his dream of working on the genetics of a simple organism. At the invitation of Luria, who was working on T series coliphages at Indiana University, Bloomington, Dulbecco joined Luria in 1947.
In 1949 Dulbecco moved to a junior faculty position at Caltech, where he continued to study bacteriophage, making use of his physics and mathematics training to analyze phage growth, recombination, and UV reactivation in a rigorous quantitative fashion. A donor had provided Caltech with a fund for studies in animal viruses, and this prompted Dulbecco to apply the lessons he had had learned from his phage work to the study of animal viruses, beginning with Western equine encephalomyelitis (WEE) virus and then turning to poliovirus, a major health problem at the time. Together with Marguerite Vogt, who became his long-term colleague, Dulbecco developed the first quantitative assays for animal viruses, setting up a plaque assay to measure WEE and poliovirus titers.
Howard Temin, a student in Dulbecco's lab, and Harry Rubin, a postdoctoral fellow, were working on Rous sarcoma virus at the time, and this piqued Dulbecco's interest in tumor viruses. He decided to work on the polyomaviruses, which constituted one of the growing number of viruses that could elicit tumors in animals. Dulbecco hoped that by studying these simple DNA tumor viruses he might be able to gain insights into the origins of human cancer.
He began his quest in the late 1950s by using two viruses: polyomavirus, a rodent tumor virus that was isolated by Stewart and Eddy in 1958 in a follow up of Ludwig Gross' earlier work; and SV40, a related simian virus discovered as a contaminant in batches of polio vaccine in 1959. Dulbecco's first paper on polyomaviruses described the ability of polyomavirus to cause plaques in mouse embryonic kidney cells in culture. It was published in 1959, and it provided the first way to measure polyomavirus titers. Subsequent papers with Marguerite Vogt characterized virus-cell interactions. They showed that when polyomavirus infects mouse embryo cells, the cells become transformed and produce virus, whereas when hamster embryo cells are infected, they are transformed but do not produce virus, which is consistent with the ability of polyomavirus to cause tumors in hamsters. Vogt and Dulbecco also demonstrated that polyomavirus contains DNA and has a circular genome.
Intrigued by Jonas Salk's vision for a new type of research institute, Dulbecco decided to join the Salk Institute in La Jolla as one of the founding fellows. He and Vogt moved to the Salk Institute in late 1963. While the main institute buildings were being constructed, they set up their laboratory in the temporary facilities in a series of trailers on the site (which are still there!), where they worked for the next 2 years before finally moving into the brand new laboratories in the north wing of the iconic Salk building on the bluffs overlooking the Pacific Ocean.
Dulbecco quickly attracted a series of outstanding postdoctoral fellows to work on polyomaviruses as a model for human cancer. A string of important papers followed. With Lee Hartwell, he showed that polyomavirus infection of mouse cells induces cellular DNA synthesis, which is a prerequisite for the virus to replicate its own DNA. With Heiner Westphal and Joe Sambrook, Dulbecco discovered that polyoma-and SV40-transformed cells express viral RNA and contain viral DNA sequences stably integrated into the host DNA. With Walter Eckhart, he showed that some temperature-sensitive polyomavirus mutants elicit temperature-dependent transformation of cells, implying that the continuous presence of a virally-encoded protein is required for transformation. These seminal findings argued strongly against the idea that tumor viruses transform cells by a hit-and-run mechanism. Dulbecco trained a truly stellar group of scientists during this period, most of whom went on to have extremely successful careers.
In 1972, Dulbecco left the Salk Institute to become Assistant Director of Research at the Imperial Cancer Research Fund (ICRF) in London. His departure left 8,000 square feet of vacant laboratory space at the Salk. This provided the opportunity to hire the first Assistant Professors at the Institute to work on tumor viruses. These appointments created the Tumor Virology Laboratory, whose legacy is still in evidence at the Institute today. At ICRF, Dulbecco continued to investigate polyomavirus transformation. He and Yoshi Ito characterized the viral proteins, called T antigens, which are produced early in infection and are responsible for transformation. In particular, Dulbecco and Ito were the first to show that the virus expresses three distinct T antigens and that the middlesized T antigen, which by itself can transform fibroblasts, is membrane associated.
For his pioneering work on the mechanisms of tumor viruses, Dulbecco shared the 1975 Nobel Prize in Physiology or Medicine with Temin and David Baltimore, who both had trained with Dulbecco at different times. Dulbecco's work on DNA tumor viruses influenced a whole generation and many of his trainees and their descendants populated the burgeoning field of tumor virology. His instinct that tumor viruses would provide insights into human cancer proved prescient and subsequent work on SV40 and polyomavirus transforming proteins pinpointed several key growth control pathways that are activated by mutations in cancer cells, such as tyrosine phosphorylation.
Dulbecco returned to the Salk Institute in 1977 to begin an entirely new program in mammary carcinogenesis and used the newly developed monoclonal antibody technology to identify surface proteins on normal mammary cells. This allowed him to identify several different types of mammary cells and to define possible roles for these cells in normal mammary development. This also enabled him to study how mutagens might perturb the normal function of these cells in the gland to initiate carcinogenesis. Dulbecco closed his laboratory in 1988, when asked to assume the presidency of the Salk Institute, a position in which he served with great distinction for four years. Subsequently, Dulbecco spent time in Italy organizing an Italian genome project, which ultimately failed, and heading a group at the Istituto Tecnologie Biomediche-Consiglio Nazionale delle Richerche in Milan working on mammary cancer.
Dulbecco recognized early on that mutations are likely to play an important role in carcinogenesis, and he speculated on that possibility in his 1975 Nobel Lecture. His sense of biology's place in society was already evident in his Nobel Lecture, in which he pointed out the general public disregard of the cancer risks posed by tobacco smoking and other man-made carcinogens. He realized that it would be necessary to define all the genes expressed both in normal and cancer cells and then pinpoint cancer-specific genetic changes if one wanted to fully understand the causes of the disease and develop better treatments. This thinking led him to propose in two lectures in 1985 and 1986, and subsequently in an influential letter to Science in 1986, that an effort to sequence the human genome should be undertaken. Others had thought that this might be valuable and even feasible because of the advances in high-throughput sequencing methods, which were becoming available at the time. However, it took someone of Dulbecco's stature to bring this to the public attention and galvanize efforts in this direction. This ultimately led to the human genome project and the completion of the human genome sequence in 2001. As Dulbecco predicted, the genetic differences between normal somatic cells and cancer cells revealed by sequencing have greatly illuminated our understanding of the disease.
Dulbecco lived through an amazing period of biological discovery; his career began before the structure of DNA was known and ended after the complete sequence of the human genome had been determined and was beginning to be used for the diagnosis and treatment of cancer, a disease he had set out to conquer nearly 50 years earlier. Dulbecco had a broader vision of science than most and a keen instinct for important problems to solve. His worked influenced a whole generation of biologists-he was truly a renaissance scientist.
